Int J Colorectal Dis (2017) 32:1289–1294 DOI 10.1007/s00384-017-2860-2 ORIGINAL ARTICLE Topic infliximab injection for refractory rectal stenosis in Crohn’s disease: long-term follow-up in two patients 1,2 2 2 Niels Teich & Ingo Wallstabe & Ingolf Schiefke Accepted: 7 July 2017 /Published online: 19 July 2017 Springer-Verlag GmbH Germany 2017 . . . Abstract Keywords Infliximab Crohn’s disease Rectal stenosis Purpose TNF blockers are approved for intravenous or sub- Endoscopic balloon dilation cutaneous systemic therapy of many chronic inflammatory diseases. As it is not possible to achieve a sufficient local clinical improvement through systemic therapy in every pa- Introduction tient, diverse approaches of topical therapy using TNF blockers have been investigated in recent years. Crohn’s disease (CD) usually starts with an inflammatory dis- Methods In this paper, we report on long-term clinical results ease phenotype in the early phase and frequently progresses of originator infliximab (IFX) injections into symptomatic com- into fibrostenotic complications. Ten years after diagnosis, bined scarring and inflammatory stenoses of the rectum in two more than 50% of CD patient populations develop stricturing patients with Crohn’s disease. Aiming at high tissue IFX levels, or penetrating disease [1, 2]. After 20 years of disease, approx- 25 mg of
International Journal of Colorectal Disease – Springer Journals
Published: Jul 19, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera